Apteeus

Apteeus is a private, pre-revenue biotech specializing in accelerated drug repurposing for high-need, underserved diseases, particularly rare genetic disorders. Its core asset is a proprietary, integrated technology platform comprising the Operando® patient biopsy program, the evidenceFactory® automated screening system, and the TEE Library® of approved molecules. The company operates a collaborative business model, partnering with patient organizations, academics, and industrial players to de-risk and expedite development, aiming to demonstrate clinical efficacy before seeking partnerships or investment for further advancement.

Integrated platform for drug repurposing comprising Operando® (patient-derived primary cell isolation via biopsies), evidenceFactory® (automated, miniaturized high-throughput screening using cell imaging and mass spectrometry), and TEE Library® (proprietary collection of approved human-use molecules).

Apteeus operates in the competitive drug repurposing space, facing rivals using computational/AI methods and other experimental screening approaches. Its differentiation lies in the integrated use of patient-derived primary cells, a proprietary library of approved molecules, and a stated focus on rare monogenic diseases through deep patient association collaboration.